{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T10:36:13Z","timestamp":1789814173259,"version":"4.0.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2007,2,15]],"date-time":"2007-02-15T00:00:00Z","timestamp":1171497600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2007,3,12]]},"DOI":"10.1007\/s11095-006-9187-y","type":"journal-article","created":{"date-parts":[[2007,2,14]],"date-time":"2007-02-14T16:41:08Z","timestamp":1171471268000},"page":"679-687","source":"Crossref","is-referenced-by-count":21,"title":["Novel Cyclic Phosphate Prodrug Approach for Cytochrome P450-activated Drugs Containing an Alcohol Functionality"],"prefix":"10.1007","volume":"24","author":[{"given":"Kristiina M.","family":"Huttunen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niina","family":"M\u00e4h\u00f6nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jukka","family":"Lepp\u00e4nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jouko","family":"Veps\u00e4l\u00e4inen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risto O.","family":"Juvonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannu","family":"Raunio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Kumpulainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomi","family":"J\u00e4rvinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarkko","family":"Rautio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,2,15]]},"reference":[{"key":"9187_CR1","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1021\/jm0303812","volume":"47","author":"P. Ettmayer","year":"2004","unstructured":"P. Ettmayer, G. L. Amidon, B. Clement, and B. Testa. Lessons learned from marketed and investigational prodrugs. J. Med. Chem. 47:2393\u20132404 (2004).","journal-title":"J. Med. Chem."},{"key":"9187_CR2","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/S1359-6446(05)03698-6","volume":"10","author":"K. Petrak","year":"2005","unstructured":"K. Petrak. Essential properties of drug-targeting delivery systems. Drug Discov. Today 10:1667\u20131673 (2005).","journal-title":"Drug Discov. Today"},{"key":"9187_CR3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0169-409X(01)00109-0","volume":"47","author":"P. C. Rensen","year":"2001","unstructured":"P. C. Rensen, R. L. De Vrueh, J. Kuiper, M. K. Bijsterbosch, E. A. Biessen, and T. J. Van Berkel. Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting. Adv. Drug Deliv. Rev. 47:251\u2013276 (2001).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"9187_CR4","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1248\/bpb.28.195","volume":"28","author":"M. Nishikawa","year":"2005","unstructured":"M. Nishikawa. Development of cell-specific targeting systems for drugs and genes. Biol. Pharm. Bull. 28:195\u2013200 (2005).","journal-title":"Biol. Pharm. Bull."},{"key":"9187_CR5","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1535-6108(03)00057-6","volume":"3","author":"G. Payne","year":"2003","unstructured":"G. Payne. Progress in immunoconjugate cancer therapeutics. Cancer Cell 3:207\u2013212 (2003).","journal-title":"Cancer Cell"},{"key":"9187_CR6","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1096\/fj.04-2747rev","volume":"19","author":"S. M. Moghimi","year":"2005","unstructured":"S. M. Moghimi, A. C. Hunter, and J. C. Murray. Nanomedicine: current status and future prospects. FASEB J. 19:311\u2013330 (2005).","journal-title":"FASEB J."},{"key":"9187_CR7","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1021\/tx0002583","volume":"14","author":"F. P. Guengerich","year":"2001","unstructured":"F. P. Guengerich. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem. Res. Toxicol. 14:611\u2013650 (2001).","journal-title":"Chem. Res. Toxicol."},{"key":"9187_CR8","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1021\/jm970664s","volume":"41","author":"C. Meier","year":"1998","unstructured":"C. Meier, M. Lorey, and E. De Clercq. cycloSal-2\u2032,3\u2032-dideoxy-2\u2032,3\u2032-didehydrothymidine monophosphate (cycloSal-d4TMP): synthesis and antiviral evaluation of a new d4TMP delivery system. J. Med. Chem. 41:1417\u20131427 (1998).","journal-title":"J. Med. Chem."},{"key":"9187_CR9","doi-asserted-by":"crossref","first-page":"8079","DOI":"10.1021\/jm050641a","volume":"48","author":"C. Meier","year":"2005","unstructured":"C. Meier, U. G\u00f6rbig, C. M\u00fcller, and J. Balzarini. cycloSal-PMEA and cycloAmb-PMEA: potentially new phosphonate prodrugs based on the cycloSal-pronucleotide approach. J. Med. Chem. 48:8079\u20138086 (2005).","journal-title":"J. Med. Chem."},{"key":"9187_CR10","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1021\/ja031818y","volume":"126","author":"M. D. Erion","year":"2004","unstructured":"M. D. Erion, K. R. Reddy, S. H. Boyer, M. C. Matelich, J. Gomez-Galeno, R. H. Lemus, B. G. Ugarkar, T. J. Colby, J. Schanzer, and P. D. Van Poelje. Design, synthesis, and characterization of a series of cytochrome P(450) 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver. J. Am. Chem. Soc. 126:5154\u20135163 (2004).","journal-title":"J. Am. Chem. Soc."},{"key":"9187_CR11","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1124\/jpet.104.075903","volume":"312","author":"M. D. Erion","year":"2005","unstructured":"M. D. Erion, P. D. Van Poelje, D. A. Mackenna, T. J. Colby, A. C. Montag, J. M. Fujitaki, D. L. Linemeyer, and D. A. Bullough. Liver-targeted drug delivery using HepDirect prodrugs. J. Pharmacol. Exp. Ther. 312:554\u2013560 (2005).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"9187_CR12","first-page":"109","volume":"7","author":"M. D. Erion","year":"2006","unstructured":"M. D. Erion, D. A. Bullough, C.-C. Lin, and Z. Hong. HepDirect prodrugs for targeting nucleotide- based antiviral drugs to the liver. Curr. Opin. Investig. Drugs 7:109\u2013117 (2006).","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"9187_CR13","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1021\/jm00362a013","volume":"26","author":"D. Farquhar","year":"1983","unstructured":"D. Farquhar, N. J. Kuttesch, M. G. Wilkerson, and T. Winkler. Synthesis and biological evaluation of neutral derivatives of 5-fluoro-2\u2032-deoxyuridine 5\u2032-phosphate. J. Med. Chem. 26:1153\u20131158 (1983).","journal-title":"J. Med. Chem."},{"key":"9187_CR14","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1021\/jm00147a043","volume":"28","author":"D. Farquhar","year":"1985","unstructured":"D. Farquhar and R. Smith. Synthesis and biological evaluation of 9- [5\u2032-(2- oxo-1,3,2-oxazaphosphorinan-2-yl)-\u03b2-D-arabinosyl]adenine and 9-[5\u2032-(2-oxo-1,3,2- dioxaphosphorinan-2-yl)-\u03b2-arabinosyl]adenine: potential neutral precursors of 9-[\u03b2-D- arabinofuranosyl]adenine 5\u2032-monophosphate. J. Med. Chem. 28:1358\u20131361 (1985).","journal-title":"J. Med. Chem."},{"key":"9187_CR15","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1517\/17425247.2.3.451","volume":"2","author":"F. Kesisoglou","year":"2005","unstructured":"F. Kesisoglou and E. M. Zimmermann. Novel drug delivery strategies for the treatment of inflammatory bowel disease. Expert Opin. Drug Deliv. 2:451\u2013463 (2005).","journal-title":"Expert Opin. Drug Deliv."},{"key":"9187_CR16","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1093\/clinchem\/28.10.2007","volume":"28","author":"D. W. Moss","year":"1982","unstructured":"D. W. Moss. Alkaline phosphatase isoenzymes. Clin. Chem. 28:2007\u20132016 (1982).","journal-title":"Clin. Chem."},{"key":"9187_CR17","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/BF01675618","volume":"18","author":"M. Asada-Kubota","year":"1986","unstructured":"M. Asada-Kubota and S. Kanamura. Intracellular localization of alkaline phosphatase in freshly isolated foetal rat hepatocytes. Histochem. J. 18:500\u2013506 (1986).","journal-title":"Histochem. J."},{"key":"9187_CR18","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1023\/A:1015840329786","volume":"9","author":"A. S. Kearney","year":"1992","unstructured":"A. S. Kearney and V. J. Stella. The in vitro enzymic labilities of chemically distinct phosphomonoester prodrugs. Pharm. Res. 9:497\u2013503 (1992).","journal-title":"Pharm. Res."},{"key":"9187_CR19","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1023\/A:1018934200343","volume":"10","author":"M. Safadi","year":"1993","unstructured":"M. Safadi, R. Oliyai, and V. J. Stella. Phosphoryloxymethyl carbamates and carbonates-novel water-soluble prodrugs for amines and hindered alcohols. Pharm. Res. 10:1350\u20131355 (1993).","journal-title":"Pharm. Res."},{"key":"9187_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/jmra.1996.0094","volume":"120","author":"R. Laatikainen","year":"1996","unstructured":"R. Laatikainen, M. Niemitz, U. Weber, J. Sundelin, T. Hassinen, and J. Veps\u00e4l\u00e4inen. General strategies for total-lineshape-type spectral analysis of NMR spectra using integral-transform iterator. J. Magn. Reson. 120:1\u201310 (1996).","journal-title":"J. Magn. Reson."},{"key":"9187_CR21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejps.2004.10.006","volume":"24","author":"M. Turpeinen","year":"2005","unstructured":"M. Turpeinen, J. Uusitalo, J. Jalonen, and O. Pelkonen. Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay. Eur. J. Pharm. Sci. 24:123\u2013132 (2005).","journal-title":"Eur. J. Pharm. Sci."},{"key":"9187_CR22","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0957-4166(99)00487-5","volume":"11","author":"G. Singh","year":"2000","unstructured":"G. Singh and H. Vankayalapati. A new glycosylation strategy for the synthesis of mannopyranosides. Tetrahedron: Asymmetry 11:125\u2013138 (2000).","journal-title":"Tetrahedron: Asymmetry"},{"key":"9187_CR23","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1080\/004982598238886","volume":"28","author":"O. Pelkonen","year":"1998","unstructured":"O. Pelkonen, J. M\u00e4enp\u00e4\u00e4, P. Taavitsainen, A. Rautio, and H. Raunio. Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica 28:1203\u20131253 (1998).","journal-title":"Xenobiotica"},{"key":"9187_CR24","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0731-7085(03)00171-7","volume":"32","author":"M. Nobilis","year":"2003","unstructured":"M. Nobilis, J. Kopecky, J. Kvetina, Z. Svoboda, M. Pour, J. Kunes, M. Holcapek, and L. Kolarova. Comparative biotransformation and disposition studies of nabumetone in humans and minipigs using high-performance liquid chromatography with ultraviolet, fluorescence and mass spectrometric detection. J. Pharm. Biomed. Anal. 32:641\u2013656 (2003).","journal-title":"J. Pharm. Biomed. Anal."}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-006-9187-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-006-9187-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-006-9187-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T03:09:26Z","timestamp":1587352166000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-006-9187-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2,15]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,3,12]]}},"alternative-id":["9187"],"URL":"https:\/\/doi.org\/10.1007\/s11095-006-9187-y","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2,15]]}}}